Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 10/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.33 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988370 | 0.90 | FURIN (0.41) | FURINC3AR1HTTSMN1; SMN2KLKB1 | |
| SCHEMBL30988364 | 0.90 | FURIN (0.42) | FURINC3AR1HTTSMN1; SMN2 | |
| SCHEMBL22690514 | 0.86 | FURIN (0.41) | FURINC3AR1HTTSMN1; SMN2KLKB1 | |
| SCHEMBL17637464 | 0.86 | FURIN (0.41) | FURINC3AR1HTTSMN1; SMN2KLKB1 | |
| SCHEMBL19026283 | 0.85 | FAP (0.38) | FURINC3AR1HTTSMN1; SMN2 | |
| SCHEMBL19026282 | 0.85 | FAP (0.38) | FURINC3AR1HTTSMN1; SMN2 | |
| SCHEMBL18931388 | 0.85 | FAP (0.38) | FURINC3AR1HTTSMN1; SMN2 | |
| SCHEMBL25787504 | 0.85 | FURIN (0.40) | FURINC3AR1HTTSMN1; SMN2KLKB1 | |
| SCHEMBL15699736 | 0.85 | FURIN (0.40) | FURINC3AR1HTTSMN1; SMN2KLKB1 | |
| SCHEMBL22138596 | 0.84 | FURIN (0.39) | FURINHTTSMN1; SMN2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135306-B2 | Antibody-drug conjugates | CHO Pharma Inc. (TW) | 2021-10-05 | — | — | US | disclosed |
| US-20190328895-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2019-10-31 | — | — | US | disclosed |
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328895-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ADCY1, NEU1 | FURIN 2375/4885C3AR1 411/4885HTT 2326/4885 |
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ST6GAL1, PA2G4 | FURIN 3186/4885C3AR1 660/4885HTT 3230/4885 |
| US-11135306-B2 | Antibody-drug conjugates | CSGALNACT1, ST6GAL1, PA2G4 | FURIN 3186/4885C3AR1 660/4885HTT 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.